-
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
Belite Bio completes enrollment in DRAGON II trial for Stargardt disease
-
BofA Securities Starts Belite Bio, Inc, ADR (BLTE) at Buy
-
Belite Bio (BLTE) Reiterated at Overweight by Cantor Fitzgerald
-
Morgan Stanley Starts Belite Bio, Inc, ADR (BLTE) at Overweight
-
Belite Bio, Inc, ADR (BLTE) PT Raised to $187 at Benchmark on Positive Phase 3 Dragon Trial Results
-
Mizuho Upgrades Belite Bio, Inc, ADR (BLTE) to Outperform
-
Cantor Fitzgerald Assumes Belite Bio, Inc, ADR (BLTE) at Overweight
-
Mizuho Starts Belite Bio, Inc, ADR (BLTE) at Neutral
-
Belite Bio, Inc, ADR (BLTE) PT Raised to $140 at Maxim Group
-
Belite Bio (BLTE) Tops Q3 EPS by 22c
-
Belite Bio receives UK regulatory nod for Stargardt disease drug application
-
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
Belite Bio receives China NMPA priority review for Stargardt treatment
-
Belite Bio, Inc, ADR (BLTE) PT Lowered to $98 at H.C. Wainwright
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) Following PIPE Transaction
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
Belite Bio (BLTE) Tops Q2 EPS by 8c
-
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
Cantor Fitzgerald Reiterates Overweight Rating on Belite Bio, Inc, ADR (BLTE)
-
Belite Bio (BLTE) Tops Q1 EPS by 10c
-
Belite Bio, Inc, ADR (BLTE) PT Raised to $80 at Benchmark
-
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
Belite Bio (BLTE) Reports In-Line Q4 EPS
-
Belite Bio, Inc, ADR (BLTE) PT Raised to $79 at Benchmark
-
Belite Bio, Inc, ADR (BLTE) PT Raised to $100 at H.C. Wainwright
-
Belite Bio (BLTE) Tops Q3 EPS by 1c
-
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
Belite Bio (BLTE) Misses Q2 EPS by 26c
-
Belite Bio, Inc, ADR (BLTE) PT Raised to $60 at H.C. Wainwright
-
Belite Bio, Inc (BLTE) Misses Q1 EPS by 5c

